HLR1 Antibody

What is HLR1 Antibody and what receptor does it target?

HLR1 is a monoclonal antibody specifically designed to recognize human interferon lambda receptor 1 (IFN-λR1). It belongs to a panel of novel monoclonal antibodies developed to study type III interferon receptor biology. The antibody targets the extracellular domain of IFN-λR1, which serves as the specific receptor component for type III interferons (IFN-λs). These interferons play crucial roles in innate immune responses, particularly during viral infections at mucosal barriers .

What are the basic characteristics of HLR1 Antibody?

HLR1 has the following key characteristics:

• Clone designation: 10H11-2-11

• Isotype: IgG1 kappa

• ELISA binding performance: Strong

• Flow cytometry performance: Poor

• Neutralization capability: Complete inhibition of IFN-λ1-mediated signaling

• Specificity: Targets human IFN-λR1 with no cross-reactivity to type I interferon receptors

The antibody characteristics have been extensively documented through binding and functional assays, establishing its profile for research applications .

What experimental methods are commonly used to validate HLR1 Antibody specificity?

Researchers typically validate HLR1 specificity through multiple complementary approaches:

• Enzyme-linked immunosorbent assay (ELISA) - Used to confirm antigen specificity and binding strength to purified recombinant IFN-λR1 proteins

• Flow cytometry - Applied to test binding capacity to cell surface IFN-λR1 on various cell lines, including comparison between wild-type and IFN-λR1 knockout cell lines

• Neutralization assays - Employed to measure inhibition of IFN-λ1-mediated gene expression (e.g., measuring expression of interferon-stimulated genes like IFIT1, OAS1, and MX1)

• Specificity controls - Testing against type I interferons (IFN-α, IFN-β) to confirm selective inhibition of type III interferon pathways only

What is the relationship between IFN-λR1 mRNA expression and protein detection by HLR1?

Understanding the correlation between IFNLR1 mRNA expression and protein detection is crucial when using HLR1 antibody. Research indicates that IFNLR1 mRNA levels do not always correlate with cell surface protein expression, presenting challenges for researchers relying solely on transcriptomic data. This discrepancy has been observed in several cell lines and primary cells, where notable differences exist between mRNA expression databases (such as Human Protein Atlas) and protein detection using antibodies like HLR1. This phenomenon highlights the importance of directly measuring receptor protein levels on cell surfaces rather than inferring expression solely from mRNA data .

What is the neutralizing capacity of HLR1 Antibody against type III interferons?

HLR1 demonstrates complete neutralizing capacity against IFN-λ1-mediated signaling pathways. In functional assays, HLR1 completely inhibited the induction of interferon-stimulated genes (ISGs) including IFIT1, OAS1, and MX1 in response to IFN-λ1 stimulation. Importantly, this neutralization is highly specific to type III interferon pathways, as HLR1 showed no inhibitory effect on gene induction mediated by type I interferons (IFN-α or IFN-β). This selective neutralization capability makes HLR1 a valuable tool for differentiating between type I and type III interferon biological activities in experimental systems .

How can researchers distinguish between HLR1 and other anti-IFN-λR1 antibodies for specific applications?

When selecting the appropriate anti-IFN-λR1 antibody for specific applications, researchers should consider the following comparison table of characteristics across the antibody panel:

This comparison facilitates informed selection based on research needs, with HLR14 emerging as the most versatile for multiple applications, while HLR1 excels specifically in ELISA and neutralization assays despite limitations in flow cytometry applications .

What methodological approaches are used to assess HLR1 antibody neutralization of IFN-mediated activities?

To assess neutralization capabilities of HLR1, researchers typically employ the following methodological approach:

• Cell culture preparation: Utilize responsive cell lines such as A549 (lung epithelial cells) known to express IFN-λR1 and respond to both type I and type III interferons

• Preincubation step: Mix target interferons (IFN-λ1, IFN-λ3, IFN-α, or IFN-β) with various concentrations of HLR1 antibody

• Stimulation of cells: Treat cells with the antibody-cytokine mixture for defined time periods (typically 4-24 hours)

• Gene expression analysis: Measure the expression of canonical interferon-stimulated genes (ISGs) such as IFIT1, OAS1, and MX1 using quantitative PCR

• Data normalization: Calculate percent inhibition relative to control samples (cells treated with interferons alone)

• Specificity controls: Include type I interferons to confirm the selectivity of neutralization for type III interferon pathways

This systematic approach provides quantitative assessment of neutralization potency and specificity profiles of HLR1 compared to other antibodies in the panel .

What technical considerations should researchers be aware of when using HLR1 for detecting cell surface IFN-λR1?

When using HLR1 for detecting cell surface IFN-λR1, researchers should consider these important technical factors:

• Detection method limitations: HLR1 demonstrates poor performance in flow cytometry despite strong ELISA binding, suggesting potential epitope accessibility issues on native receptors

• Confirmation strategies: Consider using alternative antibodies like HLR14 for flow cytometry verification of cell surface expression

• Validation with genetic controls: Include IFNLR1 knockout cell lines as negative controls and FLAG-tagged IFN-λR1 overexpressing lines as positive controls

• Background signal assessment: Carefully evaluate secondary antibody-only controls to establish proper gating and background thresholds

• Primary cell considerations: Be aware that detection sensitivity may vary across different primary cell types, with lower detection rates in cells with naturally low receptor expression

Recognizing these limitations and implementing appropriate controls will strengthen experimental interpretation when working with challenging target proteins like IFN-λR1 .

How does HLR1 antibody contribute to understanding the distinction between type I and type III interferon signaling?

HLR1 antibody serves as a valuable tool for delineating functional differences between type I and type III interferon signaling pathways. By specifically neutralizing IFN-λ1 without affecting IFN-α/β activities, researchers can selectively inhibit type III signaling while preserving type I interferon responses. This selective neutralization capability enables:

• Dissection of relative contributions of each pathway during viral infections

• Identification of genes specifically regulated by type III but not type I interferons

• Evaluation of tissue-specific responses, particularly at mucosal barriers where type III interferons play predominant roles

• Investigation of temporal dynamics between different interferon systems during immune responses

• Study of pathway-specific receptor expression patterns across diverse cell populations

These applications advance our understanding of the unique biological roles of type III interferons distinct from the more broadly expressed type I interferon system .

How can researchers optimize HLR1 antibody use in ELISA-based detection systems?

To optimize HLR1 antibody use in ELISA-based detection systems, researchers should follow these methodological approaches:

• Antigen preparation: Use properly folded recombinant IFN-λR1 extracellular domain proteins expressed in mammalian systems to preserve conformational epitopes

• Titration optimization: Perform antibody concentration titrations (typically starting at 1-10 μg/ml) to determine optimal signal-to-noise ratios

• Blocking conditions: Utilize 1-5% BSA or similar blocking agents to minimize non-specific binding

• Detection systems: Consider using high-sensitivity detection methods such as chemiluminescence for maximal detection capability

• Specificity controls: Include related receptor proteins (IL-10R2-ECD, IFN-AR2-ECD) as negative controls to confirm binding specificity

• Validation with competing antibodies: Consider competitive binding assays with other anti-IFN-λR1 antibodies to characterize epitope relationships

Following these optimization strategies will maximize detection sensitivity while ensuring specificity when using HLR1 antibody in ELISA applications .

What control antibodies should be included when using HLR1 in experimental designs?

When designing experiments with HLR1 antibody, researchers should include the following controls:

• Isotype-matched control: Mouse IgG1 kappa isotype control at equivalent concentrations to account for non-specific binding

• Secondary antibody-only control: To establish background signal thresholds

• Non-neutralizing anti-IFN-λR1 antibodies: Such as HLR5, which binds poorly and shows minimal neutralization activity

• Anti-type I interferon receptor antibodies: To distinguish pathway-specific effects when studying mixed interferon responses

• Cross-reactivity controls: Test HLR1 against non-target cytokine stimulations to confirm specificity

How can researchers troubleshoot inconsistent results when using HLR1 antibody in research?

When encountering inconsistent results with HLR1 antibody, researchers should systematically address potential issues:

• Antibody degradation assessment:

  • Verify antibody integrity through SDS-PAGE analysis

  • Consider fresh aliquoting practices to minimize freeze-thaw cycles

  • Validate activity with positive control samples known to work previously

• Cell-specific variables:

  • Confirm target receptor expression levels through complementary methods

  • Consider cell culture conditions that might affect receptor expression

  • Verify cell viability and passage number effects on experimental outcomes

• Technical considerations:

  • Reassess antibody working concentrations through titration experiments

  • Optimize incubation times and temperatures for binding studies

  • Consider buffer composition effects on antibody-antigen interactions

• Assay-specific troubleshooting:

  • For neutralization assays: verify cytokine activity before antibody addition

  • For ELISAs: evaluate plate binding, blocking, and washing conditions

  • For flow cytometry: consider fixation methods and epitope accessibility issues

Systematic evaluation of these potential variables will help identify sources of inconsistency and improve experimental reproducibility .

How can HLR1 antibody be used to study IFN-λ receptor expression across different cell types?

While HLR1 demonstrates limitations in flow cytometry applications, researchers can still utilize it within a comprehensive approach to study IFN-λ receptor expression patterns:

• Combined antibody approach:

  • Use HLR1 in ELISA/neutralization assays paired with HLR14 for flow cytometry

  • Correlate protein detection with functional responses across cell types

• Multi-method validation:

  • Compare receptor presence detected by antibodies with mRNA expression data

  • Use receptor knockout models to confirm specificity of detection signals

  • Correlate with functional responsiveness to IFN-λ stimulation

• Primary cell applications:

  • Investigate expression on immune cell subsets like plasmacytoid dendritic cells and B cells

  • Compare expression patterns between tissue-resident cells and peripheral blood populations

  • Assess expression changes during inflammatory conditions or pathogen exposure

This integrated approach provides more comprehensive understanding of receptor distribution and regulation than relying solely on transcriptomic data, which has been shown to not always correlate with protein expression levels .

What research questions about IFN-λ biology can be specifically addressed using HLR1 antibody?

HLR1 antibody enables researchers to address several critical questions in IFN-λ biology:

• Pathway specificity investigation:

  • Which cellular responses are exclusively mediated by type III vs. type I interferons?

  • How do cells integrate signals from multiple interferon pathways during infections?

• Tissue-specific immunity exploration:

  • What is the relative contribution of IFN-λ signaling in mucosal barrier protection?

  • How does selective blockade of IFN-λ signaling affect pathogen clearance at different anatomical sites?

• Therapeutic intervention potential:

  • Can selective neutralization of IFN-λ pathways modulate autoimmune conditions?

  • Would blocking IFN-λ signaling affect antiviral responses differentially across tissues?

• Receptor regulation mechanisms:

  • What factors govern IFN-λR1 protein expression independent of mRNA levels?

  • How does receptor internalization and recycling affect sensitivity to IFN-λ stimulation?

• Cross-talk with other cytokine systems:

  • How does IFN-λ signaling interact with IL-10 family cytokines that share receptor components?

  • What are the cooperative or antagonistic relationships between type I and type III interferon systems?

These research directions leverage HLR1's specific neutralization capacity to dissect the unique biological roles of the type III interferon system in immunity and disease .